Alopecia Global Market Analysis 2024

$4,500.00 – $7,000.00

The Global Alopecia Market is projected to reach $4.92 billion by 2028, from a value of $3.12 billion in 2022, by registering a CAGR of 7.9% during the forecast period 2022 – 2028

Clear
SKU: ER1093 Category:
Print  Copy  Download  
© Epson Research 2021
Share this infographic on
Published Year:
2024
Region:
Global
Forecast period:
2021-2027
Report Coverage:

Market Trends and analysis of the crucial market segments across North America, Europe, Asia Pacific and Rest of the World.

Report Format:
PDF
most popular

Single User License

$ 4,500

  • Access to one user
  • One print only
  • PDF & Excel Formats

5 User License

$ 5,500

  • Access to Five users
  • Print upto 5 copies
  • PDF & Excel Formats

Corporate User License

$ 7,000

  • Unlimited users within company
  • Free Yearly update
  • PDF & Excel Formats

The Global Alopecia Market is projected to reach $4.92 billion by 2028, from a value of $3.12 billion in 2022, by registering a CAGR of 7.9% during the forecast period. Rising awareness among patients about alopecia and its treatments, increasing government initiatives, supportive regulations & laws, improvements in healthcare infrastructure, lifestyle changes, increased PCOS levels and a growing trend of cosmetic procedures are the major factors propelling the growth of the market. However, lack of awareness among individuals, high costs of treatment, adverse effects of therapies, and unavailability of established healthcare facilities are hampering the market growth. Moreover, increasing awareness regarding hair loss is increasing the demand for pain-less therapy with minimal side effects creating ample opportunities across the globe.

Recent Developments

In February 2021, Sun Pharmaceutical Industries Ltd announced that it website for Sun Pharmaceutical’s long-term care (LTC) division, www.sunltc.com, has been launched in the United States.

In August 2020, Sun Pharmaceutical Industries Ltd. launched Flu Guard (Favipiravir 200 mg) launched in India at an affordable price of for the treatment of mild to moderate Covid-19 cases, The only oral antiviral treatment approved in India for the treatment of patients with mild to moderate Covid-19 disease is favipiravir.

In October 2019, Drizalma SprinkleTM (duloxetine delayed-release capsules) announced that it has been approved for oral use in the United States by its wholly-owned subsidiaries. Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat a variety of neuropsychiatric and pain disorders in patients who have trouble swallowing, which affects about 30-35 per cent of long-term care residents.

Competitive Landscape

CAPILLUS, Sun Pharmaceutical Industries Ltd., Cipla Inc., Merck and Co., Inc., Transitions Hair, Follica, Inc., Johnson and Johnson Services, Inc., Concert Pharmaceuticals, HCell Inc., GlaxoSmithKline plc., Cambrex Corporation are some of the major players in the Global Alopecia Market.
?

Related products

  • Placeholder
    Pharmaceuticals

    Insomnia Global Market Analysis 2024

     $4,500.00 – $7,000.00

    The Insomnia Market is projected to reach $7,807.43 million by 2028, from a value of $5,441.77 million in 2022, by registering a CAGR of 6.2% during the forecast period 2022 – 2028

TABLE OF CONTENTS

1 Summary
2 Market Overview
2.1 Abstract
2.2 Research Sources
2.3 Research Findings
2.4 Assumptions
3 Market Dynamics
3.1 Drivers & Opportunities
3.2 Restraints & Threats
3.3 Regulatory Affairs
3.4 Supplychain Analysis
3.5 PORTERS Analysis
4 Competitive Landscape
5 Alopecia Market by Type
5.1 Shampoos and Conditioners
5.2 Medicine Product
6 Alopecia Market by Disease Type
6.1 Traumatic Alopecia
6.2 Traction Alopecia
6.3 Telogen Rffluvium
6.4 Cicatricial Alopecia
6.5 Androgenetic Alopecia
6.6 Anagen Effluvium
6.7 Alopecia Universalis
6.8 Alopecia Totalis
6.9 Alopecia Neoplastica
6.10 Alopecia Mucinosa
6.11 Alopecia Areata
7 Alopecia Market by Route of Administration
7.1 Topical
7.2 Oral
7.3 Injectable
8 Alopecia Market by Treatment
8.1 Pharmaceuticals
8.2 Devices
9 Alopecia Market by Gender
9.1 Male
9.2 Female
10 Alopecia Market by Treatment Type
10.1 Topical Minoxidil
10.2 Topical Immunotherapy
10.3 Topical Corticosteroids
10.4 Oral Corticosteroids
10.5 Methotrexate
10.6 JAK Inhibitors
10.7 Immunosuppressant
10.8 Corticosteroid
10.9 Anthralin Cream Or Ointment
10.10 Alpha Reductase Inhibitors
11 Alopecia Market by Treatment Sales Channel
11.1 Prescriptions
11.2 OTC (Over-the-Counter)
12 Alopecia Market by Treatment End User
12.1 Homecare Settings
12.2 Dermatology Clinics
13 Alopecia Market by Regions
13.1 North America
13.2 Europe
13.3 Asia Pacific
13.4 Rest of the World
14 Company Profiles
14.1 CAPILLUS
14.2 Sun Pharmaceutical Industries Ltd.
14.3 Cipla Inc.
14.4 Merck and Co., Inc.
14.5 Transitions Hair
14.6 Follica, Inc.
14.7 Johnson and Johnson Services, Inc.
14.8 Concert Pharmaceuticals
14.9 HCell Inc.
14.10 GlaxoSmithKline plc.
14.11 Cambrex Corporation
14.12 Flu Guard

Inquiry
Request Customization